INJ USTEKINUMAB 90 MG
Indian Navy
VISAKHAPATNAM, ANDHRA PRADESH
Posted:
18 July 2025
Closed:
28 July 2025
GEM
GEM
Open Tender for Ustekinumab solution for Intravenous infusion stelara 130 mg 26 ml,Ustekinumab solution for Subcuta in PUNE, MAHARASHTRA
Bid Publish Date
26-Apr-2025, 9:47 am
Bid End Date
17-May-2025, 10:00 am
EMD
₹31,811
Location
Progress
RAIssue26-Apr-2025, 9:47 am
Reverse Auction03-Jun-2025, 5:00 pm
AwardPending
Quantity
990
Bid Type
Two Packet Bid
Categories
8
A tender has been published for Indian Army Ustekinumab solution for Intravenous infusion stelara 130 mg 26 ml, Ustekinumab solution for Subcutaneous stelara 90 mg 1 ml, Recombinant Factor VIII Human Plasma Albumin Free Viral Inactivation through solvent detergent treatment step Vial of 500 IU, Recombinant factor VIII Extended half life 1000 unit Vial, Dinoprostone PEG2 10 mg Pessary, Inj Faricimab in PUNE, MAHARASHTRA. Quantity: 990 by. Submission Deadline: 17-05-2025 10: 00: 00. Check eligibility and apply.
Documents 4
GeM-Bidding-7680135.pdf
Main Document
BOQ Document
BOQ
BOQ Document
BOQ
GEM General Terms and Conditions Document
GEM_GENERAL_TERMS_AND_CONDITIONS
Past Similar Tenders
(Historical Results)
5 found
Histopaque, 6x100ml,Hisep LSM 1073, 500ml,Accutase,500ml,bFGF, Human Recombinant,Human M CSF Recomb
Indian Council Of Medical Research (icmr)
PONDICHERRY, PUDUCHERRY
Posted:
23 May 2025
Closed:
13 June 2025
GEM
FARCIMAB 6MG/0.05 ML 120MG/ML SOLUTION FOR INTRAVITREAL INJECTION IN DOES VIAL WITH FILTER TRANSFER
Indian Navy
VISAKHAPATNAM, ANDHRA PRADESH
Posted:
12 August 2025
Closed:
2 September 2025
GEM
TRASTUZUMAB DERUXTECAN CONCENTRATE SOLUTION FOR INFUSION 100 MG
Indian Navy
MUMBAI, MAHARASHTRA
Posted:
3 July 2025
Closed:
24 July 2025
GEM
80134501100096 - ANTI SERA-B, MONOCLONAL,PACK 10 or 2X5ML,80133501200077 - ANTI AB GROUP SERA VIAL
Rourkela Steel Plant
SUNDERGARH, ODISHA
Posted:
12 June 2025
Closed:
2 July 2025
GEM
Tender Results
Loading results...
Bill of Quantities (BOQ)
6 Items
| Item # | Title | Description | Quantity | Unit | Consignee | Delivery (Days) |
|---|---|---|---|---|---|---|
| 1 | Ustekinumab solution for Intravenous infusion stelara 130 mg 26 ml | Ustekinumab solution for Intravenous infusion stelara 130 mg 26 ml | 9 | vial | [email protected] | 30 |
| 2 | Ustekinumab solution for Subcutaneous stelara 90 mg 1 ml | Ustekinumab solution for Subcutaneous stelara 90 mg 1 ml | 3 | pfs | [email protected] | 30 |
| 3 | Recombinant Factor VIII Human Plasma Albumin Free Viral Inactivation through solvent detergent treatment step Vial of 500 IU | Recombinant Factor VIII Human Plasma Albumin Free Viral Inactivation through solvent detergent treatment step Vial of 500 IU | 600 | vial | [email protected] | 30 |
| 4 | Recombinant factor VIII Extended half life 1000 unit Vial | Recombinant factor VIII Extended half life 1000 unit Vial | 60 | vial | [email protected] | 30 |
| 5 | Dinoprostone PEG2 10 mg Pessary | Dinoprostone PEG2 10 mg Pessary | 300 | no | [email protected] | 30 |
| 6 | Inj Faricimab | Inj Faricimab | 18 | vial | [email protected] | 30 |
🤖 AI-Powered Bidder Prediction
Discover companies most likely to bid on this tender
Live AI
Historical Data
Required Documents
1
Experience Criteria
2
Past Performance
3
Bidder Turnover
4
Certificate (Requested in ATC)
5
OEM Authorization Certificate
6
OEM Annual Turnover *In case any bidder is seeking exemption from Experience / Turnover Criteria
7
the supporting documents to prove his eligibility for exemption must be uploaded for evaluation by the buyer
Reverse Auction Schedule
Start
03-Jun-2025, 5:00 pm
End
04-Jun-2025, 5:00 pm
Duration: 24 hours
Reverse Auction Document
✅ RA concluded. Check financial results for final rankings.
Frequently Asked Questions
Key insights about MAHARASHTRA tender market
What are the eligibility requirements for **GEM/2025/B/6086867**?
The eligibility requirements include being a registered entity with the necessary pharmaceutical certifications, demonstrating experience in supplying similar pharmaceutical products, and compliance with local governmental regulations applicable to pharmaceutical supplies.
What certificates are required for submission in this tender?
Bid submissions must include technical certificates for Ustekinumab solutions and the Recombinant Factor VIII products, compliance with quality standards such as ISO, and proof of adherence to Good Manufacturing Practices (GMP).
How do I register for this tender, and what document formats are accepted?
To register for this tender, bidders must create an account on the designated procurement portal. Accepted document formats for submission are PDF and Word files. It is important to ensure all documents are complete and compliant with the tender specifications.
What are the EMD details, and what are the performance security requirements?
The Earnest Money Deposit (EMD) amount is specified in the tender documentation and serves as a commitment from the bidders. Additionally, successful bidders will be required to submit a performance security, typically a percentage of the contract value, to ensure fulfillment of the contract terms.
How will the evaluation and selection process be conducted?
The evaluation process will assess both technical and financial aspects of the bids. Factors such as compliance with technical standards, competitive pricing, and supplier reliability and past performance will be critical in determining the winning bid. Notifications of results will be communicated through official channels as specified in the documentation.
Explore More Opportunities
Quick Access
Unlock Tender Documents
Sign up now to access all documents
Performance Analytics
7-metric analysis with year-wise breakdown
Competitor Intelligence
Multi-dimensional analysis across 6 parameters
Market Penetration
By department, ministry, geography & category
Historical Analysis
Complete tender history with results
Documents 4
GeM-Bidding-7680135.pdf
Main Document
BOQ Document
BOQ
BOQ Document
BOQ
GEM General Terms and Conditions Document
GEM_GENERAL_TERMS_AND_CONDITIONS